A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer - Wikidata - awgldk - TriplyDB

A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer

A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer

http://www.wikidata.org/entity/Q36614276

about

Recurrent epithelial ovarian cancer: pharmacotherapy and novel therapeutics.Marine pharmacology in 2005-2006: antitumour and cytotoxic compounds.Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma.Current data of targeted therapies for the treatment of triple-negative advanced breast cancer: empiricism or evidence-based?Efficacy of trabectedin in patients with advanced or metastatic alveolar soft-part sarcoma.Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program.Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of trabectedin (ET-743, Yondelis) induced neutropenia.Advances in breast cancer: pathways to personalized medicine Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors.Trabectedin (ET-743): evaluation of its use in advanced soft-tissue sarcoma.Modulation of trabectedin (ET-743) hepatobiliary disposition by multidrug resistance-associated proteins (Mrps) may prevent hepatotoxicity A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies.Phase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignancies Recent advances in systemic therapy. When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer.Trabectedin: an anticancer drug from the sea.Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer.Wide-spectrum characterization of trabectedin: biology, clinical activity and future perspectives.Trabectedin combined with liposomal doxorubicin in women with relapsed ovarian cancer.Trabectedin has a low cardiac risk profile: a comprehensive cardiac safety analysis.Cytotoxic drugs for patients with breast cancer in the era of targeted treatment: back to the future?Trabectedin for the treatment of breast cancer.Macrophage Polarization: Anti-Cancer Strategies to Target Tumor-Associated Macrophage in Breast Cancer.A phase II trial of trabectedin in triple-negative and HER2-overexpressing metastatic breast cancer.Therapy-related acute myeloid leukemia following treatment with trabectedin for Ewing's sarcoma.Starvation tactics using natural compounds for advanced cancers: pharmacodynamics, clinical efficacy, and predictive biomarkers.Emerging drugs in metastatic breast cancer A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials

P2860

Q30444706-3B086B24-8A62-4782-96FF-C4A5866282A5 Q33359943-114BE2F1-4DCB-4E20-AE42-9C1732481CCF Q33381641-8A98DA38-DC3C-4F74-B05F-69EB6E0AAD2C Q33500786-6D1719B8-AA52-4038-8EC4-864F2F59BED4 Q34368039-E6F0D095-8DA9-4B22-A6F8-0EAD72D86B67 Q34578850-4188EAE8-EAB7-4C34-9121-0AF03199678C Q34580659-C75AFD35-E6D7-4EA8-BCCD-D9B8A7280575 Q35951346-DE495E28-8BCF-4309-9B5C-A10E2579C29F Q36567662-3915AC4D-5FE4-41C3-8FB4-7FA53CB2386E Q36895793-ED445C27-6855-4A82-8A5A-2E8504FA8FED Q36948681-CA0BE01D-35B9-473A-A66D-AB97331BD3C6 Q37005569-E410F950-D4DA-4244-B6E3-34B912BB5FD5 Q37163139-F809A617-9EDD-4D30-AEF0-5399863E94DC Q37360151-3492C9AD-A015-480D-A2BA-9BD71EC54954 Q37594790-D082EF0C-379B-4486-8B46-3CF5A7BEFE9D Q37622701-46951531-5CE0-4AA1-806F-ACC7BC00BAE9 Q37760957-CC800C50-9483-42D6-8EDB-BA7DD6F8E1C3 Q37765581-A7B17FE1-3B23-4F9C-994C-DD9DE8301CAD Q37854494-AC7CFA07-CAD3-4CF7-9446-683589DDAEB8 Q37928232-A7EB6A4C-1C2A-4FD7-B4FA-A6292D4F4DC9 Q38642314-040E48A5-A1F1-43C4-A85E-734403570602 Q39096364-A89B94FB-47D0-4BAB-A82B-8F035503AC36 Q45024922-1C3EA771-4F36-4899-BB22-F29A0138BA3A Q45988744-9489B535-745A-4A0E-BC86-6A9384ED287B Q55365628-FA48D45D-00B5-4108-8509-2FDF84F920D3 Q57142532-42793EAF-703B-45D3-AC13-8CDE16D677AF Q57570787-8E872F6E-B487-4CCB-A2D2-0492E70358AC

P2860

A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer

http://www.wikidata.org/entity/Q36614276

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

A phase II study of Yondelis ( ...... treated advanced breast cancer

@ast

A phase II study of Yondelis ( ...... treated advanced breast cancer

@en

type

label

A phase II study of Yondelis ( ...... treated advanced breast cancer

@ast

A phase II study of Yondelis ( ...... treated advanced breast cancer

@en

prefLabel

A phase II study of Yondelis ( ...... treated advanced breast cancer

@ast

A phase II study of Yondelis ( ...... treated advanced breast cancer

@en

P1433

Q36614276-3F150F96-CD1E-4767-8FCF-5ABE53028ADB

P1476

Q36614276-9F24AC1D-3227-4B8D-92EA-D4EEF651C9A0

P2093

Q36614276-02E04540-99FA-4858-A5BE-D2337F929D39

Q36614276-0762A61B-13B9-4D71-9CDE-81319630AC58

Q36614276-0933FE69-5F9B-4D8F-B473-E055FC6EF25D

Q36614276-1CE1509B-6EB6-4D12-9F6B-EE7D00309D17

Q36614276-30ABF8CF-E0D0-4E86-82CA-49D623AC1731

Q36614276-7D6A0B9B-626A-41B1-BBCA-9DFF8CB2BAD9

Q36614276-83D89204-9C9C-44DC-AC04-981BAAB23159

Q36614276-A2759A09-CF04-41ED-AAA2-F6BCAAD067A6

Q36614276-C227DC4F-E5E7-4AC3-9AF7-9AD71F441DDC

P2860

Q36614276-33E606CF-7524-47AD-AD5F-68DF8861D354

Q36614276-44368001-F9ED-4057-98AE-E9DDA12F3EF2

Q36614276-62E44299-4857-42DB-BCA5-A2EC424EC4C8

Q36614276-6405B30B-8284-4803-8A59-CFDCC8576F04

Q36614276-6D09C996-34C9-481F-81E7-9D964B484BBB

Q36614276-74225215-9BD7-47E0-853D-F23745BE83E3

Q36614276-9A0B8195-9F9A-4E2A-8AC0-B8431052C357

Q36614276-B73B73CB-32CE-4914-AC68-6DFF02841E5F

Q36614276-CE0BCE01-135B-499F-A3DB-C04FED8D257A

Q36614276-D9EC68C0-4663-486A-968B-103332CF36B2

P2888

Q36614276-04478DCF-D22C-42BD-AE3B-98BDA175B89C

P304

Q36614276-159CB1C7-E4E7-4859-9D7B-52E888053840

P31

Q36614276-E013B5EE-E56F-461E-95F1-CE5724C8B902

P356

Q36614276-35B15A61-29FF-4C61-8561-A99EB760B3F9

P407

Q36614276-1428AC10-944A-4586-BCC8-23F3AACE4513

P433

Q36614276-427A379D-440C-4145-A1E3-21215E22108D

P478

Q36614276-D1E6343A-93BF-467B-9ACF-C2ACE58B2C75

P577

Q36614276-4A385519-B1D4-4D21-90C2-7B01B2486760

P5875

Q36614276-26C2E39B-CD6E-41FE-9D35-21BF74B4957B

P698

Q36614276-9F730626-1454-4C28-8DBA-378F5319CF96

P932

Q36614276-3351C028-319F-417D-A530-2BC56ED550D4

P356

P1433

British Journal of Cancer

P1476

A phase II study of Yondelis ( ...... treated advanced breast cancer

@en

P2093

A Taamma

http://www.w3.org/2001/XMLSchema#string

A Yovine

http://www.w3.org/2001/XMLSchema#string

E Brain

http://www.w3.org/2001/XMLSchema#string

F Turpin

http://www.w3.org/2001/XMLSchema#string

J Jimeno

http://www.w3.org/2001/XMLSchema#string

J L Misset

http://www.w3.org/2001/XMLSchema#string

L Zelek

http://www.w3.org/2001/XMLSchema#string

M Riofrio

http://www.w3.org/2001/XMLSchema#string

M Spielmann

http://www.w3.org/2001/XMLSchema#string

P2860

Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair.

Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors.

Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study.

Preclinical and clinical results with the natural marine product ET-743.

Unique features of the mode of action of ET-743.

Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patients.

Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies.

Overcoming multidrug drug resistance in P-glycoprotein/MDR1-overexpressing cell lines by ecteinascidin 743.

Sequence-dependent synergistic cytotoxicity of ecteinascidin-743 and paclitaxel in human breast cancer cell lines in vitro and in vivo.

The combination of yondelis and cisplatin is synergistic against human tumor xenografts.

P2888

P304

1610-1614

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6603142

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

94

http://www.w3.org/2001/XMLSchema#string

P577

2006-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7046895

http://www.w3.org/2001/XMLSchema#string

P698

16736024

http://www.w3.org/2001/XMLSchema#string

P932

2361304

http://www.w3.org/2001/XMLSchema#string